2023
Identifying factors that influence the decision to reduce, delay, or discontinue treatment due to chemotherapy-induced peripheral neuropathy: A community-centered approach.
Radwan R, Hertz D, Hickey E, Vachhani H, Lustberg M, Bridges J, Sabo R, Sheppard V, Salgado T. Identifying factors that influence the decision to reduce, delay, or discontinue treatment due to chemotherapy-induced peripheral neuropathy: A community-centered approach. Journal Of Clinical Oncology 2023, 41: e13123-e13123. DOI: 10.1200/jco.2023.41.16_suppl.e13123.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyMetastatic breast cancerPeripheral neuropathyTreatment alterationsTreatment effectivenessMBC patientsCIPN symptomsMedical oncologistsDiscontinue treatmentClinical guidelinesOncology cliniciansCommunity-centered approachEffective therapyBreast cancerChemotherapy agentsTreatment decisionsPatient prioritiesPatient's perspectiveDose reductionAlternative treatmentOptimize outcomesPatientsSide effectsTreatment planHealthcare providers
2010
Epigenetic Therapy in Breast Cancer
Lustberg M, Ramaswamy B. Epigenetic Therapy in Breast Cancer. Current Breast Cancer Reports 2010, 3: 34-43. PMID: 23097683, PMCID: PMC3477864, DOI: 10.1007/s12609-010-0034-0.Peer-Reviewed Original ResearchEpigenetic changesHistone deacetylase inhibitorsMajor epigenetic changesNucleosome remodelingHistone modificationsEpigenetic regulationEpigenetic mechanismsDNA methylationGene sequencesEpigenetic therapyGene expressionDemethylating agentDeacetylase inhibitorsMultistep processBreast cancerEpigeneticsBreast carcinogenesisGenesMethylationSystemic therapyClinical trialsEffective therapyReversible processRegulationSingle agent